Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: model analysis from the perspective of Germany's statutory health insurance system


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
20678682

DOI
10.1016/j.clinthera.2010.07.010

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Aged, 80 and over; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Choroidal Neovascularization /drug therapy /economics; Cost-Benefit Analysis; Drug Costs; Germany; Humans; Insurance, Health, Reimbursement /economics; Macular Degeneration /drug therapy /economics; Markov Chains; Middle Aged; Models, Economic; Monte Carlo Method; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ranibizumab; Visual Acuity /drug effects

AccessionNumber
22010001489

Date bibliographic record published
22/12/2010